Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)

This study has been completed.
Sponsor:
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00153998
First received: September 8, 2005
Last updated: February 26, 2009
Last verified: April 2007

September 8, 2005
February 26, 2009
November 2004
March 2008   (final data collection date for primary outcome measure)
Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population
Tumor response, defined as partial and complete response according to RECIST- criteria in the intention-to-treat [ITT-] population
Complete list of historical versions of study NCT00153998 on ClinicalTrials.gov Archive Site
  • Rate of R0 liver resection (ITT- population)
  • Progression free survival (ITT- population)
  • Disease free survival after resection (ITT- population)
  • Overall survival (ITT- population)
  • Safety (all patients that received any study drug)
  • Molecular predictive markers for response and toxicity
Same as current
Not Provided
Not Provided
 
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases

General Objectives:

  • To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection
  • To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chemotherapy

Patients with liver metastasis will be screened for this study. Eligible patients will complete the pretreatment evaluation including an abdominal CT scan that will be presented to the local surgeon and the radiologist for proving of resectability of hepatic lesions. Additionally, CT scans will be reviewed by three reference surgeons. In case of non-resectability, as defined above, CT- or ultrasound- guided biopsy of one of the liver metastases will be performed, unless biopsy material is available from prior biopsy of one of the liver metastases.

Instead of an ultrasound-guided biopsy, a CT-guided biopsy may be performed.

Formalin-fixed, paraffin embedded metastatic tissue will be sent to reference laboratory (Prof. Störkel, Wuppertal) for immunohistochemical analysis of EGFR- expression.

Additionally tissue will be stored in "RNA later" for gene expression analysis if agreed by the patient.

Additionally, the primary tumor will be collected and sent to the reference laboratory for analysis of EGFR- expression (if agreement of the patient exists).

Patients will be randomized to a combination of:

Cetuximab/FOLFIRI (irinotecan/5-FU/FA) or Cetuximab/FOLFOX6 (oxaliplatin/5-FU/FA)

All patients receive a four month treatment (eight cycles) of the allocated treatment.

Resection is planned after completion of neoadjuvant treatment and should be performed between 4 and 6 weeks after the last dose of chemotherapy. Probes of the resected material (in liquid nitrogen and paraffin embedded material will be collected).

If a resection is not possible after eight administrations of chemotherapy, chemotherapy will be continued until tumor progression (maximal duration of treatment 2 years) and the patient will be evaluated for a potential resection every two months.

After resection, postoperative treatment is planned for 3 months (6 cycles). Treatment start is planned between 4 and 8 weeks after the operation.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Colorectal Cancer
  • Liver Metastases
  • Drug: Cetuximab
  • Procedure: Liver resection
  • Drug: Cetuximab and FOLFIRI

    Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:

    Cetuximab 250 mg/m² (1.0 h i.v.) weekly

    Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)

    Other Names:
    • Cetuximab(C225, Erbitux®, Merck KGaA)
    • Irinotecan (irinotecan HCl, CPT-11 or Campto®, Aventis)
    • 5-Fluorouracil (5-FU)
    • Folinic acid (FA, i.e. Leucovorin®, Wyeth)
  • Drug: Cetuximab and FOLFOX

    Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:

    Cetuximab 250 mg/m² (1.0 h i.v.) weekly

    Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)

    Other Names:
    • Cetuximab(C225, Erbitux®, Merck KGaA)
    • Oxaliplatin (L-OHP, Eloxatin®, Sanofi-Synthelabo)
    • 5-Fluorouracil (5-FU)
    • Folinic acid (FA, i.e. Leucovorin®, Wyeth)
  • Active Comparator: 1
    Cetuximab and FOLFIRI
    Interventions:
    • Drug: Cetuximab
    • Procedure: Liver resection
    • Drug: Cetuximab and FOLFIRI
  • Active Comparator: 2
    Cetuximab and FOLFOX
    Interventions:
    • Drug: Cetuximab
    • Procedure: Liver resection
    • Drug: Cetuximab and FOLFOX

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
135
Not Provided
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with non-resectable, histologically confirmed, synchronous or metachronous colorectal liver metastases. Patients with non-resectable metastases are defined as; patients with five or more liver metastases; and/or patients with liver metastases that are technically non-resectable (local surgeon in cooperation with local radiologist will define non-resectability on the basis of remaining functional liver tissue, infiltration of all liver veins, infiltration of both liver arteries, both portal branches or both bile ducts).
  • Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior to chemotherapy.
  • Karnofsky Performance Status ≥ 80
  • Informed consent
  • Adequate bone marrow function, liver and renal function (neutrophils > 1.5 x 10^9/l; thrombocytes > 100 x 10^9/l; hemoglobin > 8.0 g/l; bilirubin ≤ 1.5 x upper limit of normal [ULN] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT < 5 x UNL; serum creatinine ≤ 1.5 x UNL)
  • Age ≥ 18 years

Exclusion Criteria:

  • Any evidence of extrahepatic metastases, lymph node metastases and primary tumor recurrence
  • Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)
  • Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy
  • Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or port implantation) ≤ 4 weeks before study entry
  • Concurrent systemic immune therapy, chemotherapy, or hormone therapy
  • Investigational agents or participation in clinical trials within 30 days before start of the treatment in study
  • Clinically relevant coronary disease or myocardial infarction within 12 months before study entry
  • Peripheral neuropathy > CTC grade I
  • Inflammatory bowel disease
  • Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
  • History of severe psychiatric illness
  • Drug or alcohol abuse
  • Breast feeding or pregnant women, no effective contraception if risk of conception exists (male and female patients)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Germany
 
NCT00153998
CELIM
No
Prof. Dr. Claus-Henning Köhne, now: Klinikum Oldenburg gGmbH
Technische Universität Dresden
Not Provided
Principal Investigator: Claus-Henning Köhne, Prof. Dr. Klinikum Oldenburg GmbH, Dr.-Eden-Str.10; 26133 Oldenburg
Principal Investigator: Gunnar Folprecht, Dr. University Hospital Dresden, Fetscherstr. 74, 01307 Dresden, Germany
Technische Universität Dresden
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP